



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/914,454	01/14/2002	Guido Grandi	PP01591.101	4170
7590	05/02/2007			
Alisa A Harbin Chiron Corporation Intellectual Property R-338 P O Box 8097 Emeryville, CA 94662-8097				EXAMINER MINNIFIELD, NITA M
			ART UNIT 1645	PAPER NUMBER PAPER
			MAIL DATE 05/02/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b><i>Office Action Summary</i></b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/914,454	GRANDI ET AL.
<b>Examiner</b>	<b>Art Unit</b>	
N. M. Minnifield	1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

1)  Responsive to communication(s) filed on 12 February 2007.

2a)  This action is **FINAL**.                    2b)  This action is non-final.

3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## **Disposition of Claims**

4)  Claim(s) 1-6,8-21,23-25,27-39 and 43-45 is/are pending in the application.  
4a) Of the above claim(s) 27-39 is/are withdrawn from consideration.

5)  Claim(s) \_\_\_\_\_ is/are allowed.

6)  Claim(s) 1-4,6,8-21,23,24 and 43-45 is/are rejected.

7)  Claim(s) 5 and 25 is/are objected to.

8)  Claim(s) 27-39 are subject to restriction and/or election requirement.

## Application Papers

9)  The specification is objected to by the Examiner.

10)  The drawing(s) filed on \_\_\_\_\_ is/are: a)  accepted or b)  objected to by the Examiner.

    Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

    Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)  The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

12)  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a)  All    b)  Some \* c)  None of:  
1.  Certified copies of the priority documents have been received.  
2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

1)  Notice of References Cited (PTO-892) 4)  Interview Summary (PTO-413)  
2)  Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date. \_\_\_\_.  
3)  Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date  
5)  Notice of Informal Patent Application  
6)  Other: \_\_\_\_.

**DETAILED ACTION**

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on February 12, 2007 has been entered.
2. Claims 7, 22, 26 and 40-42 have been canceled. Claims 1-6, 8-21, 23-25, 27-39 and 43-45 are now pending in the present application. All rejections have been withdrawn in view of Applicants' amendment to the claims and/or comments, with the exception of those discussed below.
3. Claims 1-6, 8-21, 23-25 and 43-45 have been examined in the instant application.
4. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
5. This application contains claims 27-39 have been drawn to an invention nonelected with traverse in the paper filed January 24, 2005. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

6. Claims 1-4, 6, 8-21, 23, 24 and 43-45 are rejected under 35 U.S.C. 103(a) as being unpatentable over Claassen et al (Vaccine, 1996, 14/10:1001-1008), Garcon et al (WO 98/56414), in view of Krieg et al (WO 98/18810) and Schwartz et al (WO 98/55495).

Claim 1 is directed to an immunogenic composition comprising: an immunostimulating amount of a *Neisseria* antigen; and an immunostimulating amount of an adjuvant composition comprising: (i) an oligonucleotide comprising at least one CG motif; and (ii) an emulsion comprising submicron oil droplets and an emulsifying agent, wherein the ratio of the emulsifying agent to the oil in said emulsion allows production of an emulsion wherein at least 80% of said oil droplets are less than 1 micron in diameter.

Claassen et al teaches a composition comprising a *Neisseria meningitidis* antigen, proteins from *Neisseria meningitidis* serogroup b, and an adjuvant (abstract; materials and methods, p. 1002). Claassen et al teaches the use of aluminum phosphate as the adjuvant.

Garcon et al teaches that oil in water emulsions having an oil droplet diameter of substantially 300-600 nm diameters in size (i.e. less than 1 micron in diameter) and that they can be used as vaccine adjuvants (abstract; p. 4; claims). The adjuvants comprise metabolisable oil squalene (i.e. a terpenoid), alpha-tocopherol and TWEEN80 (p. 1). Garcon et al teaches that the emulsion may be used own its own or with other adjuvants or immunostimulants (p. 4). Garcon et al teaches the use of polyoxyethylene sorbitan monooleate (TWEEN 80), an emulsifying agent (p. 5). Garcon et al teaches that the vaccine formulation can contain an antigen and that the antigen can be derived from bacterial pathogens such as *Neisseria* spp., including *N. gonorrhoea* and *N. meningitidis* (for example

capsular polysaccharides and conjugates thereof, transferring-binding proteins, lactoferrin binding proteins, PilC, adhesions) (see p. 5). Garcon et al teaches that the composition comprise 2 to 10% squalene (i.e. 0.5 to 20% oil) and 0.3 to 3% TWEEN80, the emulsifying agent (i.e. 0.01 to 0.5% emulsifying agent) (see p. 10). Claassen et al and Garcon et al teach the claimed invention except for the adjuvant composition comprising an oligonucleotide comprising at least one CG motif.

However, Krieg et al teaches that CpG oligonucleotides are immunostimulatory and are useful as synthetic adjuvants (abstract; p. 1; claims). Krieg et al teaches that the oligonucleotides can be used to treat, prevent or ameliorate disorders that include bacterial infection (p. 10). The infectious bacteria include *Neisseria gonorrhoeae* and *Neisseria meningitidis* (p. 17). The prior art teaches that the oligonucleotide can have a phosphorothioate bond (p. 22). “Nonspecific simulators of the immune response are known as adjuvants. The use of adjuvants is essential to induce a strong antibody response to soluble antigens (reference omitted). The overall effect of adjuvants is dramatic and their importance cannot be overemphasized. The action of an adjuvant allows much smaller doses of antigen to be used and generates antibody responses that are more persistent. The nonspecific activation of the immune response often can spell the difference between success and failure in obtaining an immune response. Adjuvants should be used for first injections unless there is some very specific reason to avoid this.” (p. 33, l. 30-38) Krieg et al teach the claimed SEQ ID NO: 1. “Recently an intense drive to find potent adjuvants with more acceptable side effects has led to the production of new synthetic adjuvants. The present invention provides the sequence 1826 TCCATGACGTTCCCTGACGTT (SEQ ID NO: 10), which is an adjuvant including CpG containing nucleic acids. The sequence is a

strong immune activating sequence and is a superb adjuvant, with efficacy comparable or superior to complete Freund's, but without apparent toxicity." (p. 34, l. 15-20) Krieg et al teaches the use of additional adjuvants in the composition. "Immunostimulatory oligonucleotides and unmethylated CpG containing vaccines, which directly activate lymphocytes and co-stimulate an antigen-specific response, are fundamentally different from conventional adjuvants (e.g. aluminum precipitates), which are inert when injected alone and are thought to work through absorbing the antigen and thereby presenting it more effectively to immune cells. Further, conventional adjuvants only work for certain antigens; only induce an antibody (humoral) immune response (Th2), and are very poor at inducing cellular immune responses (Th1). For many pathogens, the humoral response contributes little to protection, and can even be detrimental." (p. 65, l. 1-8)

Schwartz et al teaches a composition comprising an immunostimulatory oligonucleotide (CpG) and antigen (abstract). Schwartz et al teaches that the antigen can be protein, glycoproteins, polysaccharides and lipids (p. 4, l. 33-34; p. 12, l. 9-28; pp. 12-13). "In another embodiment, the immunomodulatory composition comprises an oligonucleotide that contains at least one immunostimulatory (ISS) octanucleotide and a facilitator selected from the group consisting of co-stimulatory molecules, cytokines, chemokines, targeting protein ligand, a trans-activating factor, a peptide, and a peptide comprising a modified amino acid." (p. 4, l. 36-39; p. 12, l. 9-28) Schwartz et al teaches that the composition can also comprise the oligonucleotide, an antigen and an adjuvant (p. 5, l. 1-2; p. 8, l. 19-23). The adjuvants include alum, lipid emulsions and polylactide/polyglycolide microparticles as well as oil-in-water emulsions, mycobacterium cell wall preparations and muramyl peptide (p. 12; pp. 15-19;

claims). Schwartz et al teaches that the compositions provide for methods of treating subjects in need of immune modulation; the subjects may be suffering from infectious diseases and bacterial infections (p. 5; claims). Schwartz et al teaches that the CG motif be flanked by two purines immediately 5' to said motif and two pyrimidines immediately 3' to said motif (p. 7, l. 14-21). Schwartz et al teaches that an immunomodulatory facilitators, molecules which support and/or enhance the immunomodulatory activity of an oligonucleotide, can be used in the composition, which include cytokines and/or adjuvants (p. 14, l. 15-36), as well as compositions comprising an oligonucleotide, antigen and adjuvant (claims).

In view of the combined teachings of Claassen et al, Garcon et al, Krieg et al and Schwartz et al it would have been obvious to a person of ordinary skill in the art to prepare a composition that comprises a *Neisseria* antigen, CG oligonucleotide and emulsion and optionally another adjuvant. The prior art teaches that the *Neisseria* antigen can be *Neisseria meningitidis*, *Neisseria gonorrhoeae* an antigen from *Neisseria meningitidis* serogroup B (Claassen et al and Garcon et al). An adjuvant composition comprising an oligonucleotide comprising at least one CG motif and an emulsion are taught in Krieg et al, Schwartz et al and Garcon et al. Krieg et al teaches the claimed oligonucleotide as set forth in SEQ ID NO: 1 and teaches that it is a strong immune activating sequence and is a superb adjuvant. Krieg et al, Schwartz et al and Garcon et al teach the use of multiple adjuvants and/or immunostimulants in the compositions. Schwartz et al teaches that the specifically claimed additional adjuvants can be used in the compositions to enhance the immunomodulatory activity. The claimed invention is *prima facie* obvious in view of the combination of teachings as a

whole found in Claassen et al, Garcon et al, Krieg et al and Schwartz et al, absent any convincing evidence to the contrary.

7. Claims 5 and 25 are objected to because they depend from a rejected claim

8. No claims are allowed.

9. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is 571-272-0860. The examiner can normally be reached on M-F (8:00-5:30) Second Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



N. M. Minnifield

Primary Examiner

Art Unit 1645

NMM

April 29, 2007